Clinical DevelopmentRP-3467 shows potential for significant tumor volume reductions, including clearance, in combination with PARP inhibitors.
Financial StabilityRepare's cash runway extends into late-2027, providing financial stability and possibly further extended by the new agreement.
Strategic PartnershipsRepare Therapeutics Inc announced an agreement with DCx Biotherapeutics to outlicense their preclinical discovery engines in exchange for $4M cash and other incentives.